What does this research mean for the field?

Treatment with reni-cel, a CRISPR-Cas12a gene-editing therapy targeting HBG1 and HBG2 promoters, normalizes total hemoglobin levels, increases fetal hemoglobin, and effectively prevents vaso-occlusive events in patients with severe sickle cell disease. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the effectiveness of CRISPR-Cas12a gene editing on HBG1 and HBG2 promoters in the treatment of sickle cell disease.

April 5, 2026

CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat Sickle Cell Disease

Key Points

To evaluate the effectiveness of CRISPR-Cas12a gene editing on HBG1 and HBG2 promoters in the treatment of sickle cell disease.
Administered reni-cel treatment to participants
Monitored total hemoglobin levels and fetal hemoglobin percentages
Tracked vaso-occlusive events post-infusion
Normalized total hemoglobin levels observed in participants
Increase in fetal hemoglobin percentage in treated patients
No vaso-occlusive events recorded in 27 out of 28 patients

Abstract

Treatment with reni-cel led to normalization of the total hemoglobin level and an increase in the percentage of fetal hemoglobin, with no vaso-occlusive events occurring in 27 of 28 patients after infusion. These results support further investigation of this gene-editing approach in the treatment of severe sickle cell disease. (Funded by Editas Medicine; RUBY ClinicalTrials.gov number, NCT04853576.).

AI से पूछें

Bookmark